In 2006, IOCB and Gilead expanded their long-term partnership and collaboration, establishing a program called Gilead Sciences Research Centre at IOCB Prague. In the program, Gilead donated annually $1.1 million for five years to selected research groups at IOCB to expand their efforts in the field of human disease research.
Since then, the program has been renewed twice in 2011 and 2016 with increased funding of $1.35 million annually.
Supported research projects
- Natural product-inspired macrocycles – Concert of theory and synthesis toward biological activity (PI: Ullrich Jahn)
- Immune competent mouse models of CHB (PI: Gabriel Birkuš)
- Towards novel strategies to target chronic hepatitis B (PI: Iva Pichová)
- Chemical biology tools for drug discovery (PI: Jan Konvalinka)
- Design, synthesis and biological profiling of novel fused deazapurine nucleosides (PI: Michal Hocek)
- Targeting enzyme exosites by in situ click chemistry: New strategy for anticancer drug design (PI: Pavlína Maloy Řezáčová)
- Small-molecule inhibitors of viral replication (PI: Radim Nencka)
- Novel potent inhibitors of key purine salvage enzymes (PI: Zlatko Janeba)
- Enzymatically stable galectin inhibitors (PI: Radek Pohl)